Huang, B.T., Li, K.F., Wu, X.S., Zhang, F.Y. and Li, Y.P. (2025) Application and Research Advancement of Antibody-Conjugated Drugs in Non-Small Cell Lung Cancer. Journal of Biosciences and Medicines, ...

Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...

Incorporating genomic testing into the management of cervical cancer allows for the creation of personalized treatment plans ...

Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...

This manuscript offers valuable insights by identifying two distinct liver cancer subtypes through multi-omics integration and developing a robust prognostic model, validated across various datasets, ...

1Department of Cancer Biology and Genetics, James Comprehensive Cancer Center, Wexner Medical Center, The Ohio State University, Columbus, Ohio. 3Pelotonia Institute for Immuno-Oncology, James ...

Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu 610065, China Targeted Tracer ...

as well as the progress in the field of lung cancer treatment targeting relevant metabolic pathways. This provides some promising potential directions into exploring lung cancer tumor metabolism and ...

For locally advanced and advanced NSCLC, epidermal growth factor receptor (EGFR ... cancer or cholangiocarcinoma. However, the expression of α2,3-sialylate type 1 (SLeA) is primarily detected for ...

Dis new pathway go allow migrants and dia families to come live permanently for Australia. Di National Innovation visa dey replace di Global Talent visa wey end for 6 December. According to di ...

pathway is another important cell-proliferation pathway downstream of EGFR that is frequently activated in cancer. Although mutations in Ras oncogenes do not seem to coexist with EGFR mutations ...